Fig. 6.

Co-administration of enhancer of zeste homolog 2 (EZH2) inhibitor with gefitinib suppresses EZH2 and the EGFR signaling pathways. Cells were treated with GSK343 (11 μmol/L), DZNep (10 μmol/L), gefitinib (12 μmol/L), G + g (11 μmol/L GSK343 + 12 μmol/L gefitinib), or D + g (10 μmol/L DZNep + 12 μmol/L gefitinib). a The effects of EZH2 silencing on the levels of the EZH2 and the key molecules of EGFR/AKT pathway (EGFR, AKT, and MAPK) in A549 and H1299 cells were evaluated by western blotting. b The effects of GSK343, DZNep, and gefitinib on the the EZH2, EGFR and AKT in A549 and H1299 cells were evaluated by western blotting